Use (and Potential for Abuse) of Glucagon-Like Peptide-1 Medications Among Individuals with Eating Disorders: Empirical Review and Clinical Guidance.

Limited available data indicate that glucagon-like peptide-1 (GLP-1) medications may significantly reduce weight and binge-eating symptoms among patients with binge-eating disorder. However, experts express concern about the potential for GLP-1 medications to cause unintended harm or be misused among some individuals with eating disorders (EDs). The present review describes the state of the science surrounding use of GLP-1 medications in EDs, identifies key knowledge gaps, offers a roadmap for future studies on this topic, and provides clinical guidance to support the careful assessment and treatment of patients with EDs who may be considering the use of a GLP-1 medication.